Biogen Inc

NAS : BIIB
$232.65+1.76%Oct 16 close

Financials

Original filing

Condensed Consolidated Statements of Income (Unaudited)

USD · reported units.

Condensed Consolidated Statements of Income (Unaudited), filing 0000875045-26-000075. USD · reported units.
Reported line itemApr 1, 2026 to Jun 30, 2026 (current)Jan 1, 2026 to Jun 30, 2026Jan 1, 2025 to Jun 30, 2025Apr 1, 2025 to Jun 30, 2025
Income Statement [Abstract]
Statement [Table]
Product and Service [Axis]
Product and Service [Domain]
Product revenue, net
Revenue from anti-CD20 therapeutic programs
Alzheimer's collaboration revenue
Contract manufacturing, royalty and other revenue
Statement [Line Items]
Total revenue
Cost and expenses:
Cost of sales, excluding amortization and impairment of acquired intangible assets
Research and development
Acquired in-process research and development, upfront and milestone expense
Selling, general and administrative
Amortization and impairment of acquired intangible assets
Collaboration profit sharing/(loss reimbursement)
(Gain) loss on fair value remeasurement of contingent consideration
—
Restructuring charges
Other (income) expense, net
Total cost and expense
Income before income tax (benefit) expense
Income tax (benefit) expense
Net income attributable to Biogen Inc.
Net income per share:
Basic earnings per share attributable to Biogen Inc. (in USD per share)USD / share
Diluted earnings per share attributable to Biogen Inc. (in USD per share)USD / share
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc. (in USD per share)Shares
Diluted earnings per share attributable to Biogen Inc. (in USD per share)Shares
18 line items · 4 reported periodsOriginal filing order · parentheses indicate negative amounts

Each column reflects this filing’s presentation. Original line items and period dates are preserved.